Healthcare - Biotechnology - NASDAQ - US
$ 12.43
-3.27 %
$ 756 M
Market Cap
-3.71
P/E
CASH FLOW STATEMENT
-116 M
OPERATING CASH FLOW
-127 M
INVESTING CASH FLOW
274 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pliant Therapeutics, Inc.
| Net Income | -161 M |
| Depreciation & Amortization | 1.84 M |
| Capital Expenditures | -921 K |
| Stock-Based Compensation | 44.5 M |
| Change in Working Capital | 1.25 M |
| Others | -6.3 M |
| Free Cash Flow | -117 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (161.3) | (123.3) | (97.3) | (41.5) | (0.6) | (30.3) | (18.3) |
| Depreciation & Amortization | 1.8 | 1.8 | 1.5 | 1.3 | 1.1 | 0.7 | 0.3 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (12.2) | 0 | 0 |
| Stock Based Compensation | 44.5 | 22.6 | 10.4 | 3.9 | 1.8 | 0.2 | 33 K |
| Other Operating Activities | (2.6) | 52 K | 2.9 | 0.3 | 12.2 | 1.1 | 0.2 |
| Change in Working Capital | 1.3 | 4.2 | 6.9 | (1.2) | (5.1) | 1.1 | 0.9 |
| Cash From Operations | (116.4) | (94.6) | (75.4) | (37.3) | (2.8) | (28.3) | (16.9) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (0.9) | (1.8) | (2.0) | (1.5) | (1.0) | (2.3) | (1.4) |
| Other Items | (126.1) | (148.4) | 75.7 | (209.3) | (17.0) | 0 | 0 |
| Cash From Investing Activities | (127.0) | (150.2) | 73.7 | (210.9) | (17.9) | (2.3) | (1.4) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 12 K |
| Total Debt Repaid | 0 | 10.0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.8) | 216.9 | (0.5) | 52.0 | 45.4 | 174.7 | 20.0 |
| Cash From Financing Activities | 274.4 | 226.9 | 2.5 | 213.2 | 45.5 | 87.3 | 20.0 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 31.0 | (18.0) | 0.8 | (34.9) | 24.9 | 56.7 | 1.7 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (117.3) | (96.4) | (77.4) | (38.8) | (3.7) | (30.7) | (18.3) |